DOCSLIB.ORG

Methods of Treating Fragile X Syndrome

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Methods of Treating Fragile X Syndrome (19) TZZ __T (11) EP 2 578 216 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 10.04.2013 Bulletin 2013/15 A61K 31/195 (2006.01) A61K 31/428 (2006.01) A61K 31/215 (2006.01) A61P 25/00 (2006.01) (2006.01) (21) Application number: 12184579.6 A61P 43/00 (22) Date of filing: 21.11.2007 (84) Designated Contracting States: • Roberts, Kathryn AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Fairfield, CT Connecticut CT 06824 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE •Bear,Mark F SI SK TR Boston, MA Massachusetts MA 02118 (US) Designated Extension States: AL BA HR MK RS (74) Representative: Kirkham, Nicholas Andrew et al Graham Watt & Co. LLP (30) Priority: 22.11.2006 US 860733 P St. Botolph’s House 02.11.2007 US 1567 P 7-9 St. Botolph’s Road Sevenoaks, Kent TN13 3AJ (GB) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: Remarks: 07862184.4 / 2 083 811 •This application was filed on 14-09-2012 as a divisional application to the application mentioned (71) Applicant: Seaside Therapeutics, Inc. under INID code 62. Cambridge, MA 02139 (US) •Claims filed after the date of filing of the application (Rule 68(4) EPC). (72) Inventors: • Carpenter, Randall L Boston, MA Massachusetts MA 02116 (US) (54) Methods of treating fragile x syndrome (57) Subjects having at least one condition selected a GABA(B) agonist, such as baclofen. GABA (B) agonists from the group consisting of mental retardation, Down’s can be used in combination with Group I mGluR antag- syndrome, fragile X syndrome and autism are treated onists and MI muscarinic receptor antagonists in meth- with a composition that includes gamma-am inobutyric ods of treating humans. acid agonists and/or MI muscarinic receptor antagonists. The gamma-am inobutyric acid agonist (GABA) can be EP 2 578 216 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 578 216 A1 Description RELATED APPLICATIONS 5 [0001] This application claims the benefit of U.S. Provisional Application No. 60/860,733, filed on November 22, 2006, and U.S. Provisional Application entitled "Use of M1 Muscarinic Antagonists to Treat Disorders of Brain Development," by Randall L. Carpenter, filed November 2, 2007, Attorney Docket No.: 3933.1007-000. The entire teachings of the above applications are incorporated herein by reference. 10 BACKGROUND OF THE INVENTION [0002] Mental retardation, Down’s syndrome, fragile X syndrome and autism are developmental and genetic disorders that affect day to day functioning, including learning, memory, speech, social skills and behavior. Currently available treatment regimens for humans with mental retardation, Down’s syndrome, fragile X syndrome and to assist in day-to- 15 day functioning, include, for example, behavioral modifications and treatment with a range of medications including anti- depressant and anti-psychotic drugs. However, such regimens frequently are not effective or may produce undesirable side-effects with long term use, particularly the use of anti-psychotic drugs. Thus, there is a need to develop new, improved and effective methods to treat mental retardation, Down’s syndrome, fragile X syndrome and autism. 20 SUMMARY OF THE INVENTION [0003] The present invention relates to a method of treating humans having mental retardation, Down’s syndrome, fragile X syndrome and autism. [0004] In one embodiment, the invention is a method of treating a human, comprising the step of administering to a 25 human having at least one condition selected from the group consisting of Down’s.syndrome, fragile X syndrome and autism a composition that includes a gamma-aminobutyric acid agonist. [0005] In another embodiment, the invention is a method of treating a human, comprising the step of administering to a human having at least one condition selected from the group consisting of Down’s Syndrome, fragile X syndrome and autism a composition that includes Formula I: 30 35 40 [0006] In yet another embodiment, the invention is a method of treating a human, comprising the step of administering 45 to a human having at least one condition selected from the group consisting of mental retardation, Down’s syndrome, fragile X syndrome and autism a composition that includes baclofen, wherein the baclofen is administered to the human at a dose of about 2 mg per day for days 1, 2 and 3 of treatment, a dose of about 4 mg per day for days 4, 5 and 6 of treatment, a dose of about 6 mg per day for days 7, 8 and 9 of treatment, a dose of about 10 mg per day for days 10, 11 and 12 of treatment, a dose of about 20 mg per day for days 13, 14 and 15 of treatment, a dose of about 30 mg per 50 day for days 16, 17 and 18 of treatment and a dose between about 30 mg to about 80 mg per day for the duration of the treatment. [0007] In an additional embodiment, the invention is a method of treating a human, comprising the step of administering to a human having at least one condition selected from the group consisting of mental retardation, Down’s syndrome, fragile X syndrome and autism a composition that includes baclofen, wherein the baclofen is administered to the human 55 at a dose of about 15 mg for days 1, 2 and 3 of treatment, a dose of about 30 mg for days 4, 5 and 6 of treatment, a dose of about 45 mg for days 7, 8 and 9 of treatment, a dose of about 60 mg for days 10, 11 and 12 of treatment and a dose between about 60 mg to about 80 mg per day for the duration of the treatment. [0008] In still another embodiment, the invention is a method of treating a human, comprising the step of administering 2 EP 2 578 216 A1 to a human having at least one condition selected from the group consisting of mental retardation, Down’s syndrome, fragile X syndrome and autism a composition that includes at least about 51 mole percent S-baclofen relative to the total S-baclofen and R-baclofen in the composition administered to the human. [0009] In a further embodiment, the invention is a method of treating a human, comprising the step of administering 5 to a human having at least one condition selected from the group consisting of mental retardation, Down’s syndrome, fragile X syndrome and autism a composition that includes at least about 51 mole percent R-baclofen relative to the total R-baclofen and S-baclofen in the composition administered to the human. [0010] An additional embodiment of the invention is a method of treating a human, comprising the step of administering to a human having at least one condition selected from the group consisting of mental retardation, Down’s syndrome, 10 fragile X syndrome and autism a composition that includes baclofen, wherein the baclofen is administered to the human at a dosing regimen of at least one member selected from the group consisting of about 1 mg twice a day, about 2 mg twice a day, about 3 mg twice a day, about 5 mg twice a day, about 10 mg twice a day and about 10 mg three times a day. [0011] In yet another embodiment, the invention is a method of treating a subject, comprising the step of administering to a subject having at least one condition selected from the group consisting of mental retardation, Down’s syndrome, 15 fragile X syndrome and autism a composition that includes at least one M1 muscarinic antagonist. [0012] Advantages of the claimed invention can include, for example, treatment of mental retardation, Down’s syn- drome, fragile X syndrome and autism in a manner that can improve symptoms (e.g., reduce anxiety and irritability; increase cognitive function, communication and/or social interaction), efficacy or reduce side effects and thereby improve tolerability for use over a relatively long period of time wit hout significant side effects. The methods of the invention can 20 provide an effective manner to treat a subject having mental retardation, Down’s syndrome, fragile X syndrome and/or autism. BRIEF DESCRIPTION OF THE DRAWINGS 25 [0013] Figure 1 depicts the effects of racemic baclofen on the inhibition of marble-burying behavior in fragile X (Fmrl) knock out (KO) mice (n = 7-8 mice/group). Data are expressed as the mean 6 SEM number of marbles buried. Figure 2 depicts the effects of R(+)-baclofen on marble-burying behavior in Fmrl KO mice (n = 10-16 mice/group). 30 Data are expressed as the mean marbles buried 6 SEM. An asterik (*) indicates data for the 10 mg/kg dose was significantly less (p < 0.05) than all other groups. Figure 3 depicts the effects S(-)-baclofen on marble-burying behavior of Fmr1 KO mice (n = 11-15 mice/group). Data are expressed as the mean number of marbles buried 6 SEM. The # symbol indicates that the data for the 1 mg/kg dose was significantly greater than the 0 mg/kg dose. The asterik (*) indicates that the 50 mg/kg dose was 35 significantly different (p< 0.05) than all other groups. Figure 4 depicts the effect of R(+)-baclofen and S(-)-baclofen on audiogenic seizures in Fmr1 KO mice (n = 9-10 mice/group). Data are expressed as a percentage of mice treated with vehicle (0 mg/kg), (+)-R or S(-)-baclofen, that exhibited audiogenic seizures. Figure 5 depicts the effect of R(+)- and S(-)-baclofen on open-field activity of Fmr1 KO male mice.
Load more

Recommended publications
  • Autism Guideline Jan2018.Pdf
    DATE: January 2018 TEXAS CHILDREN’S HOSPITAL EVIDENCE-BASED OUTCOMES CENTER Screening and Diagnosis of Autism Spectrum Disorder (ASD) Evidence-Based Guideline Definition: (1) Autism Spectrum Disorder (ASD) per the DSM-5 Early Signs (2,5,6) encompasses four previously separate disorders that are Social Skills Deficits actually a single condition with different levels of symptom Early years severity in two core domains. These four disorders are the - Do not appear to seek connectedness DSM-IV Autistic Disorder (autism), Asperger’s Disorder, - Contentbeingalone Childhood Disintegrative Disorder, and Pervasive - Ignore parents’ bids for attention Developmental Disorder Not Otherwise Specified (PDD-NOS). - Seldom make eye contact or bid for others’ attention ASD is characterized in early childhood by 1) deficits in social with gestures or vocalizations communication and social interaction and 2) restricted - Deficits in joint attention repetitive behaviors, interests, and activities (RRBs). - Fail to follow a point and/or share expression - Failto point to “comment” Etiology: (2) Although ASDs are heritable neurodevelopmental - Failtorespondtoname conditions with strong genetic underpinnings, their exact - Selective hearing etiology is unknown. The etiology is multifactorial with a variety - Less imitation of genetic and, to a lesser extent, environmental factors Later years playing a role. ASDs can be either idiopathic or associated with - Difficulty sharing the emotional state of others in other diagnoses; most are idiopathic. cooperative
    [Show full text]
  • Distinct Muscarinic Acetylcholine Receptor Subtypes Contribute to Stability and Growth, but Not Compensatory Plasticity, of Neuromuscular Synapses
    14942 • The Journal of Neuroscience, November 25, 2009 • 29(47):14942–14955 Development/Plasticity/Repair Distinct Muscarinic Acetylcholine Receptor Subtypes Contribute to Stability and Growth, But Not Compensatory Plasticity, of Neuromuscular Synapses Megan C. Wright,1 Srilatha Potluri,1 Xueyong Wang,2 Eva Dentcheva,1 Dinesh Gautam,3 Alan Tessler,1,4 Ju¨rgen Wess,3 Mark M. Rich,2 and Young-Jin Son1 1Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, Pennsylvania 19129, 2Department of Neuroscience, Cell Biology, and Physiology, Wright State University, Dayton, Ohio 45435, 3Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892, and 4Department of Neurology, Department of Veterans Affairs Hospital, Philadelphia, Pennsylvania 19104 Muscarinic acetylcholine receptors (mAChRs) modulate synaptic function, but whether they influence synaptic structure remains un- known. At neuromuscular junctions (NMJs), mAChRs have been implicated in compensatory sprouting of axon terminals in paralyzed or denervated muscles. Here we used pharmacological and genetic inhibition and localization studies of mAChR subtypes at mouse NMJs to demonstrate their roles in synaptic stability and growth but not in compensatory sprouting. M2 mAChRs were present solely in motor neurons,whereasM1 ,M3 ,andM5 mAChRswereassociatedwithSchwanncellsand/ormusclefibers.BlockadeofallfivemAChRsubtypes with atropine evoked pronounced effects,
    [Show full text]
  • Tardive Dyskinesia
    Tardive Dyskinesia Tardive Dyskinesia Checklist The checklist below can be used to help determine if you or someone you know may have signs associated with tardive dyskinesia and other movement disorders. Movement Description Observed? Rhythmic shaking of hands, jaw, head, or feet Yes Tremor A very rhythmic shaking at 3-6 beats per second usually indicates extrapyramidal symptoms or side effects (EPSE) of parkinsonism, even No if only visible in the tongue, jaw, hands, or legs. Sustained abnormal posture of neck or trunk Yes Dystonia Involuntary extension of the back or rotation of the neck over weeks or months is common in tardive dystonia. No Restless pacing, leg bouncing, or posture shifting Yes Akathisia Repetitive movements accompanied by a strong feeling of restlessness may indicate a medication side effect of akathisia. No Repeated stereotyped movements of the tongue, jaw, or lips Yes Examples include chewing movements, tongue darting, or lip pursing. TD is not rhythmic (i.e., not tremor). These mouth and tongue movements No are the most frequent signs of tardive dyskinesia. Tardive Writhing, twisting, dancing movements Yes Dyskinesia of fingers or toes Repetitive finger and toe movements are common in individuals with No tardive dyskinesia (and may appear to be similar to akathisia). Rocking, jerking, flexing, or thrusting of trunk or hips Yes Stereotyped movements of the trunk, hips, or pelvis may reflect tardive dyskinesia. No There are many kinds of abnormal movements in individuals receiving psychiatric medications and not all are because of drugs. If you answered “yes” to one or more of the items above, an evaluation by a psychiatrist or neurologist skilled in movement disorders may be warranted to determine the type of disorder and best treatment options.
    [Show full text]
  • Muscarinic Acetylcholine Type 1 Receptor Activity Constrains Neurite Outgrowth by Inhibiting Microtubule Polymerization and Mito
    fnins-12-00402 June 26, 2018 Time: 12:46 # 1 ORIGINAL RESEARCH published: 26 June 2018 doi: 10.3389/fnins.2018.00402 Muscarinic Acetylcholine Type 1 Receptor Activity Constrains Neurite Outgrowth by Inhibiting Microtubule Polymerization and Mitochondrial Trafficking in Adult Sensory Neurons Mohammad G. Sabbir1*, Nigel A. Calcutt2 and Paul Fernyhough1,3 1 Division of Neurodegenerative Disorders, St. Boniface Hospital Research Centre, Winnipeg, MB, Canada, 2 Department of Pathology, University of California, San Diego, San Diego, CA, United States, 3 Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, MB, Canada The muscarinic acetylcholine type 1 receptor (M1R) is a metabotropic G protein-coupled Edited by: receptor. Knockout of M1R or exposure to selective or specific receptor antagonists Roberto Di Maio, elevates neurite outgrowth in adult sensory neurons and is therapeutic in diverse University of Pittsburgh, United States models of peripheral neuropathy. We tested the hypothesis that endogenous M1R Reviewed by: activation constrained neurite outgrowth via a negative impact on the cytoskeleton Roland Brandt, University of Osnabrück, Germany and subsequent mitochondrial trafficking. We overexpressed M1R in primary cultures Rick Dobrowsky, of adult rat sensory neurons and cell lines and studied the physiological and The University of Kansas, United States molecular consequences related to regulation of cytoskeletal/mitochondrial dynamics *Correspondence: and neurite outgrowth. In adult primary neurons, overexpression of M1R caused Mohammad G. Sabbir disruption of the tubulin, but not actin, cytoskeleton and significantly reduced neurite [email protected] outgrowth. Over-expression of a M1R-DREADD mutant comparatively increased neurite Specialty section: outgrowth suggesting that acetylcholine released from cultured neurons interacts This article was submitted to with M1R to suppress neurite outgrowth.
    [Show full text]
  • WO 2017/177262 Al 19 October 2017 (19.10.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/177262 Al 19 October 2017 (19.10.2017) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/198 (2006.01) A61P 27/02 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, A61K 31/375 (2006.01) A61P 27/10 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (21) International Application Number: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, PCT/AU20 17/0503 10 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (22) International Filing Date: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 10 April 2017 (10.04.2017) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (25) Filing Language: English ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 2016901339 11 April 2016 ( 11.04.2016) AU GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: UNIVERSITY OF CANBERRA [AU/AU]; TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, University Drive, Bruce, Australian Capital Territory 2617 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (AU).
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe Et Al
    US 2011 01 05536A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe et al. (43) Pub. Date: May 5, 2011 (54) DOSING REGIMENASSOCATED WITH Publication Classification LONG-ACTING INUECTABLE PALIPERDONE ESTERS (51) Int. Cl. A 6LX 3/59 (2006.01) (76) Inventors: Peter H. Lewyn-Briscoe, A6IP 25/18 (2006.01) Newtown, PA (US); Cristiana Gassmann-Mayer, Pennington, NJ (US); Srihari Gopal, Belle Meade, (52) U.S. Cl. ................................................... S14/259.41 NJ (US); David W. Hough, Wallingford, PA (US); Bart M.M. Remmerie, Gent (BE); Mahesh N. (57) ABSTRACT Samtani, Flemington, NJ (US) The present application provides a method for treating (21) Appl. No.: 12/916,910 patients in need of psychiatric treatment, wherein said patient (22) Filed: Nov. 1, 2010 misses a stabilized dose of a monthly maintenance regimen of paliperidone palmitate. The present application also provides Related U.S. Application Data a method for treating psychiatric patients in need of a Switch (60) Provisional application No. 61/256,696, filed on Oct. ing treatment to paliperidone palmitate in a Sustained release 30, 2009. formulation. Patent Application Publication May 5, 2011 Sheet 1 of 6 US 2011/O105536 A1 FIG. 1 First-Order PrOCeSS Cp V CL Central (2) Zero-Order PrOCeSS Patent Application Publication May 5, 2011 Sheet 2 of 6 US 2011/O105536 A1 FIG. 2 25mgeq 50mgeq m-100mde::::: Missed doSe On WK 4. Patient returns On WK5 Missed doSe On WK 4. Patient returns On WK 6 -8-4 O 4 8 12 16 2024 -8-4 O 4 8 12 1620 24 Missed doSe On WK 4.
    [Show full text]
  • Fragile X Syndrome
    AUCD Annual Conference Research Symposium The Rapidly Changing Landscape of Fragile X Elizabeth Berry-Kravis MD PhD Rush University Medical Center Disclosures: EBK has received funding from Neuropharm LTD, Seaside Therapeutics , Novartis and Roche Pharmaceuticals to consult on trial design and conduct clinical trials in FXS Features of Fragile X Syndrome • Physical: large prominent ears, long face, large head, prominent jaw and forehead, midfacial hypoplasia hyperflexible joints, large testis • Intellectual Disability or LD • Behavior problems: hyperactivity distractibility, anxiety, perseveration • Autism: 18-36% AD, 43-67% ASD • Seizures – 15% • Strabismus – 30% • Medical: otitis, sinus, MVP, reflux, sleep apnea, loose stools, allergies FXS Treatment in Clinic - Rush FXS Clinic since 1992 > 450 patients Supportive • Aggressive tx of otitis – • Early intervention tubes/audiology • Intensive speech therapy • Manage sleep apnea – • OT with sensory integration T&A • Inclusion in school as much • Treat sleep dysregulation as possible – melatonin/medications • Educational curriculum, • Yearly eye exams – environment, teaching style patching, surgery, glasses matched to FXS cognitive • Control seizures profile • Orthopedics if needed • Socialization program • Monitor for MVP/heart • Behavior plan • Genetic counseling • Behavior medications for • Discuss reproductive ADD/anxiety options Seizures in Fragile X Syndrome – Recent and Largest Study National Fragile X Survey 1394 FXS full mutation (1090 M, 304 F) 173 (12%) seizures: 154 (14%)
    [Show full text]
  • The Fragile X Syndrome and Infantile Autism: a Prevalence Study Brian Herb Annex Yale University
    Yale University EliScholar – A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 1985 The fragile X syndrome and infantile autism: a prevalence study Brian Herb Annex Yale University Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl Recommended Citation Annex, Brian Herb, "The fragile X syndrome and infantile autism: a prevalence study" (1985). Yale Medicine Thesis Digital Library. 2345. http://elischolar.library.yale.edu/ymtdl/2345 This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information, please contact [email protected]. YALE MEDICAL LIBRARY Permission for photocopying or microfilming of " TU (title of thesis) tr for the purpose of individual scholarly consultation or refer¬ ence is hereby granted by the author. This permission is not to be interpreted as affecting publication of this work, or otherwise placing it in the public domain, and the author re¬ serves all rights of ownership guaranteed under common law protection of unpublished manuscripts. (Signature of author) (Printed name) (Date) Digitized by the Internet Archive in 2017 with funding from The National Endowment for the Humanities and the Arcadia Fund https://archive.org/details/fragilexsyndromeOOanne The Fragile X Syndrome and Infantile Autism A Prevalence Study A Thesis Submitted to the Yale University School of Medicine in Partial Fulfillment of the Requirements for the degree of Doctor of Medicine by Brian Herb Annex 1985 Acknowledgments I would like to express my sincere appreciation to all those who advised and assisted me in this thesis project.
    [Show full text]
  • Known Active Compounds Used in This Article
    Known active compounds used in this article As COX-2 active compounds, 12 inhibitors and 2 natural ligands were selected. The two natural ligands were arachidonic acid and prostaglandin H2. The 12 inhibitors were diclofenac, etodolac, suprofen, diflunisal, piroxicam, sulindac, indomethacin, ketoprofen, naproxen, nimesulide, rofecoxib, and 1-phenylsulfonamide-3-trifluoromethyl-5-parabromophenylpyrazole. The names of the thermolysin inhibitors used in the present study are as follows, with the PDB code in parentheses representing the complex structure from which the compound originated: l-benzylsuccinate (1hyt), phenylalanine phosphinic acid - deamino-methyl-phenylalanine (1os0), (6-methyl-3,4-dihydro-2H-chromen-2-Yl) methylphosphonate (1pe5), 2-(4-methylphenoxy) ethylphosphonate - 3-methylbutan-1-amine (1pe7), 2-ethoxyethylphosphonate - 3-methylbutan-1-amine (1pe8), (2-sulfanyl-3-phenylpropanoyl)-Phe-Tyr (1qf0), [2(R,S)-2-sulfanylheptanoyl]-Phe-Ala (1qf1), [(2S)-2-sulfanyl-3-phenylpropanoyl]-Gly-(5-phenylproline) (1qf2), n-(1-(2(R, S)-carboxy-4-phenylbutyl) cyclopentylcarbonyl)- (S)-tryptophan (1thl), (R)-retrothiorphan (1z9g), (S)-thiorphan (1zdp), hydroxamic acid (4tln), phenylalanine phosphinic acid (4tmn), Honh-benzylmalonyl-L-alanylglycine-P-nitroanilide (5tln), 1 Cbz-GlyP-Leu-Leu (ZgPLl) (5tmn), Cbz-GlyP-(O)-Leu-Leu (ZgP(O)Ll) (6tmn), CH2CO(N-OH)Leu-OCH3 (7tln), benzyloxycarbonyl-D-Ala (1kto), benzyloxycarbonyl-L-Ala (1kl6), benzyloxycarbonyl-D-Thr (1kro), benzyloxycarbonyl-L-Thr (1kj0), benzyloxycarbonyl-D-Asp (1ks7), benzyloxycarbonyl-L-Asp
    [Show full text]
  • Patterns of Antipsychotic Prescription to Patients with Schizophrenia in Korea: Results from the Health Insurance Review & Assessment Service-National Patient Sample
    ORIGINAL ARTICLE Psychiatry & Psychology http://dx.doi.org/10.3346/jkms.2014.29.5.719 • J Korean Med Sci 2014; 29: 719-728 Patterns of Antipsychotic Prescription to Patients with Schizophrenia in Korea: Results from the Health Insurance Review & Assessment Service-National Patient Sample Seon-Cheol Park,1,2 Myung-Soo Lee,3 This study aimed to analyze the patterns of antipsychotic prescription to patients with Seung-Gul Kang,4 and Seung-Hwan Lee5 schizophrenia in Korea. Using the Health Insurance Review & Assessment Service-National Patients Sample (HIRA-NPS), which was a stratified sampling from the entire population 1 Department of Psychiatry, Yong-In Mental Hospital, under the Korean national health security system (2009), descriptive statistics for the Yongin; 2Institute of Mental Health, Hanyang University, Seoul; 3Seoul Mental Health Center & patterns of the monopharmacy and polypharmacy, neuropsychiatric co-medications, and Seoul Suicide Prevention Center, Seoul; 4Department prescribed individual antipsychotic for patients with schizophrenia were performed. of Psychiatry, Gachon University, School of Comparisons of socioeconomic and clinical factors were performed among patients 5 Medicine, Incheon; Department of Psychiatry, Inje prescribed only with first- and second-generation antipsychotics. Of 126,961 patients with University Ilsan Paik Hospital, Goyang, Korea schizophrenia (age 18–80 yr), 13,369 were prescribed with antipsychotic monopharmacy Received: 19 December 2013 and the rest 113,592 with polypharmacy. Two or more antipsychotics
    [Show full text]
  • Tourette's Syndrome
    Tourette’s Syndrome CHRISTOPHER KENNEY, MD; SHENG-HAN KUO, MD; and JOOHI JIMENEZ-SHAHED, MD Baylor College of Medicine, Houston, Texas Tourette’s syndrome is a movement disorder most commonly seen in school-age children. The incidence peaks around preadolescence with one half of cases resolving in early adult- hood. Tourette’s syndrome is the most common cause of tics, which are involuntary or semi- voluntary, sudden, brief, intermittent, repetitive movements (motor tics) or sounds (phonic tics). It is often associated with psychiatric comorbidities, mainly attention-deficit/hyperac- tivity disorder and obsessive-compulsive disorder. Given its diverse presentation, Tourette’s syndrome can mimic many hyperkinetic disorders, making the diagnosis challenging at times. The etiology of this syndrome is thought to be related to basal ganglia dysfunction. Treatment can be behavioral, pharmacologic, or surgical, and is dictated by the most incapacitating symp- toms. Alpha2-adrenergic agonists are the first line of pharmacologic therapy, but dopamine- receptor–blocking drugs are required for multiple, complex tics. Dopamine-receptor–blocking drugs are associated with potential side effects including sedation, weight gain, acute dystonic reactions, and tardive dyskinesia. Appropriate diagnosis and treatment can substantially improve quality of life and psychosocial functioning in affected children. (Am Fam Physician. 2008;77(5):651-658, 659-660. Copyright © 2008 American Academy of Family Physicians.) ▲ Patient information: n 1885, Georges Gilles de la Tourette normal context or in inappropriate situa- A handout on Tourette’s described the major clinical features tions, thus calling attention to the person syndrome, written by the authors of this article, is of the syndrome that now carries his because of their exaggerated, forceful, and provided on p.
    [Show full text]